{"id":76855,"date":"2026-11-06T04:20:16","date_gmt":"2026-11-06T04:20:16","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?p=76855"},"modified":"2026-11-06T04:32:14","modified_gmt":"2026-11-06T04:32:14","slug":"american-analyst-updates-nov-5th-2026","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/","title":{"rendered":"American Analyst Updates: Nov 5th, 2026"},"content":{"rendered":"

Analyst Ratings (USA)<\/strong><\/a><\/h2>\n

Wall Street analyst outlook fot today remains mixed and increasingly cautious, with significant downgrades across technology, software, financial services, consumer discretionary, and industrial sectors, offset by selective upgrades in renewable energy, healthcare, transportation, and infrastructure. Technology stocks faced particular pressure, with multiple downgrades in enterprise software, financial technology, and digital advertising reflecting concerns over valuations, slowing growth, and competitive pressures. Semiconductor analysts also showed greater caution, although artificial intelligence infrastructure continues to attract favourable coverage and new Buy recommendations. Consumer-related businesses experienced weaker sentiment amid concerns over spending trends and earnings expectations, while renewable energy, medical technology, and select transportation companies benefited from improving analyst confidence.<\/p>\n

Updates (734)<\/strong><\/h3>\n

3M (MMM)<\/strong> \u2014 Goldman Sachs maintains its Buy rating and raises its price target to $225.00 from $200.00.<\/p>\n

Aardvark Therapeutics (AARD)<\/strong> \u2014 Raymond James downgrades its rating from Strong Buy to Market Perform.<\/p>\n

Acadia Healthcare (ACHC)<\/strong> \u2014 Barclays maintains its Equal Weight rating and raises its price target to $35.00 from $32.00.<\/p>\n

ACADIA Pharmaceuticals (ACAD)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $38.00 from $36.00.<\/p>\n

Acadian Asset Management (AAMI)<\/strong> \u2014 Morgan Stanley upgrades its rating from Equal Weight to Overweight and raises its price target to $110.00 from $97.00.<\/p>\n

AdaptHealth (AHCO)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $8.00 from $7.00.<\/p>\n

Addus HomeCare (ADUS)<\/strong> \u2014 TD Cowen maintains its Buy rating and raises its price target to $145.00 from $131.00.<\/p>\n

Addus HomeCare (ADUS)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $148.00 from $135.00.<\/p>\n

Addus HomeCare (ADUS)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $160.00 from $145.00.<\/p>\n

Adient (ADNT)<\/strong> \u2014 JPMorgan maintains its Overweight rating and lowers its price target to $23.00 from $25.00.<\/p>\n

ADMA Biologics (ADMA)<\/strong> \u2014 Cantor Fitzgerald maintains its Neutral rating and raises its price target to $13.00 from $12.00.<\/p>\n

ADMA Biologics (ADMA)<\/strong> \u2014 Mizuho sets a price target of $18.00.<\/p>\n

Advanced Micro Devices (AMD)<\/strong> \u2014 HSBC maintains its Hold rating with a price target of $540.00.<\/p>\n

Afya (AFYA)<\/strong> \u2014 Morgan Stanley upgrades its rating from Underweight to Equal Weight with a price target of $12.60.<\/p>\n

Allegiant Travel (ALGT)<\/strong> \u2014 Raymond James maintains its Strong-Buy rating with a price target of $120.00.<\/p>\n

Allstate (ALL)<\/strong> \u2014 Barclays maintains its Underweight rating and raises its price target to $228.00 from $221.00.<\/p>\n

Amcor (AMCR)<\/strong> \u2014 Deutsche Bank downgrades its rating from Buy to Hold.<\/p>\n

Amcor (AMCR)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $53.00 from $51.00.<\/p>\n

American Bitcoin (ABTC)<\/strong> \u2014 BTIG Research maintains its Buy rating and lowers its price target to $12.00 from $15.00.<\/p>\n

American Financial Group (AFG)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $180.00 from $166.00.<\/p>\n

American International Group (AIG)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $85.00 from $83.00.<\/p>\n

American Tower (AMT)<\/strong> \u2014 Argus maintains its Buy rating with a price target of $210.00.<\/p>\n

American Water Works (AWK)<\/strong> \u2014 Huntington downgrades its rating from Outperform to Market Perform.<\/p>\n

Amgen (AMGN)<\/strong> \u2014 Guggenheim maintains its Neutral rating and raises its price target to $435.00 from $378.00.<\/p>\n

Amgen (AMGN)<\/strong> \u2014 Leerink Partners maintains its Market Perform rating and raises its price target to $464.00 from $395.00.<\/p>\n

Amneal Pharmaceuticals (AMRX)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $25.00 from $23.00.<\/p>\n

Amplitude (AMPL)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $19.00 from $17.00.<\/p>\n

Amplitude (AMPL)<\/strong> \u2014 KeyBanc Capital Markets maintains its Overweight rating and raises its price target to $22.00 from $14.00.<\/p>\n

Amplitude (AMPL)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $21.00 from $18.00.<\/p>\n

Amplitude (AMPL)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and raises its price target to $22.00 from $18.00.<\/p>\n

Amplitude (AMPL)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $22.00 from $13.00.<\/p>\n

Amylyx Pharmaceuticals (AMLX)<\/strong> \u2014 Stifel sets a price target of $45.00.<\/p>\n

Angel Oak Mortgage REIT (AOMR)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $8.00 from $10.00.<\/p>\n

Angi (ANGI)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $7.00 from $5.00.<\/p>\n

APA (APA)<\/strong> \u2014 Barclays maintains its Equal Weight rating and raises its price target to $44.00 from $40.00.<\/p>\n

APA (APA)<\/strong> \u2014 Stephens maintains its Equal Weight rating and raises its price target to $51.00 from $49.00.<\/p>\n

Appian (APPN)<\/strong> \u2014 William Blair upgrades its rating from Market Perform to Outperform.<\/p>\n

AppLovin (APP)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $450.00 from $396.00.<\/p>\n

AppLovin (APP)<\/strong> \u2014 Goldman Sachs maintains its Neutral rating and raises its price target to $445.00 from $400.00.<\/p>\n

AppLovin (APP)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating with a price target of $475.00.<\/p>\n

AppLovin (APP)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and raises its price target to $520.00 from $490.00.<\/p>\n

AppLovin (APP)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and raises its price target to $355.00 from $325.00.<\/p>\n

AppLovin (APP)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $520.00 from $500.00.<\/p>\n

AppLovin (APP)<\/strong> \u2014 Scotiabank maintains its Sector Outperform rating and lowers its price target to $450.00 from $515.00.<\/p>\n

AppLovin (APP)<\/strong> \u2014 Wedbush maintains its Outperform rating and raises its price target to $600.00 from $560.00.<\/p>\n

ArcBest (ARCB)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $175.00 from $170.00.<\/p>\n

ArcBest (ARCB)<\/strong> \u2014 JPMorgan maintains its Neutral rating and raises its price target to $164.00 from $158.00.<\/p>\n

Arcus Biosciences (RCUS)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $49.00 from $46.00.<\/p>\n

Arcus Biosciences (RCUS)<\/strong> \u2014 Truist maintains its Buy rating and lowers its price target to $40.00 from $41.00.<\/p>\n

Arcus Biosciences (RCUS)<\/strong> \u2014 Wedbush maintains its Outperform rating and lowers its price target to $45.00 from $49.00.<\/p>\n

Arcutis Biotherapeutics (ARQT)<\/strong> \u2014 Needham & Company LLC sets a price target of $40.00.<\/p>\n

Arcutis Biotherapeutics (ARQT)<\/strong> \u2014 TD Cowen maintains its Buy rating and raises its price target to $40.00 from $35.00.<\/p>\n

ARM (ARM)<\/strong> \u2014 Barclays maintains its Overweight rating and lowers its price target to $325.00 from $360.00.<\/p>\n

ARM (ARM)<\/strong> \u2014 Goldman Sachs maintains its Sell rating with a price target of $160.00.<\/p>\n

ARM (ARM)<\/strong> \u2014 HSBC maintains its Hold rating with a price target of $215.00.<\/p>\n

ARM (ARM)<\/strong> \u2014 JPMorgan maintains its Overweight rating and lowers its price target to $245.00 from $255.00.<\/p>\n

ARM (ARM)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating with a price target of $255.00.<\/p>\n

ARM (ARM)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and lowers its price target to $270.00 from $320.00.<\/p>\n

ARM (ARM)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and lowers its price target to $300.00 from $340.00.<\/p>\n

ARM (ARM)<\/strong> \u2014 TD Cowen maintains its Buy rating and lowers its price target to $250.00 from $350.00.<\/p>\n

ARM (ARM)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $255.00 from $280.00.<\/p>\n

Ashland (ASH)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $82.00 from $80.00.<\/p>\n

Assurant (AIZ)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Outperform rating and raises its price target to $345.00 from $325.00.<\/p>\n

Astera Labs (ALAB)<\/strong> \u2014 BMO Capital Markets initiates coverage with a Outperform rating and a price target of $375.00.<\/p>\n

ATI Inc. (ATI)<\/strong> \u2014 Citigroup initiates coverage with a Buy rating and a price target of $229.00.<\/p>\n

Avient (AVNT)<\/strong> \u2014 Barclays maintains its Equal Weight rating and raises its price target to $50.00 from $44.00.<\/p>\n

Avient (AVNT)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $56.00 from $50.00.<\/p>\n

Avis Budget Group (CAR)<\/strong> \u2014 Goldman Sachs maintains its Sell rating and raises its price target to $108.00 from $94.00.<\/p>\n

Avis Budget Group (CAR)<\/strong> \u2014 JPMorgan maintains its Underweight rating and lowers its price target to $85.00 from $105.00.<\/p>\n

Avnet (AVT)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $125.00 from $110.00.<\/p>\n

Avnet (AVT)<\/strong> \u2014 Wells Fargo & Company maintains its Underweight rating and raises its price target to $85.00 from $80.00.<\/p>\n

Ball (BALL)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $77.00 from $75.00.<\/p>\n

Ball (BALL)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $77.00 from $73.00.<\/p>\n

Beam Therapeutics (BEAM)<\/strong> \u2014 Guggenheim maintains its Buy rating and lowers its price target to $51.00 from $55.00.<\/p>\n

Becton, Dickinson and Company (BDX)<\/strong> \u2014 Jefferies Financial Group maintains its Buy rating with a price target of $242.00.<\/p>\n

BeOne Medicines (ONC)<\/strong> \u2014 Jefferies Financial Group maintains its Buy rating with a price target of $470.00.<\/p>\n

Beyond Meat (BYND)<\/strong> \u2014 Barclays maintains its Underweight rating and lowers its price target to $5.00 from $10.00.<\/p>\n

Billiontoone (BLLN)<\/strong> \u2014 BTIG Research maintains its Buy rating with a price target of $130.00.<\/p>\n

Billiontoone (BLLN)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $135.00 from $130.00.<\/p>\n

Bio-Rad Laboratories (BIO)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $440.00 from $390.00.<\/p>\n

BioCryst Pharmaceuticals (BCRX)<\/strong> \u2014 Wedbush maintains its Outperform rating and lowers its price target to $17.00 from $18.00.<\/p>\n

Block (XYZ)<\/strong> \u2014 Argus maintains its Buy rating and raises its price target to $105.00 from $103.00.<\/p>\n

Block (XYZ)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $105.00 from $100.00.<\/p>\n

Block (XYZ)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $110.00 from $97.00.<\/p>\n

Boise Cascade (BCC)<\/strong> \u2014 BMO Capital Markets downgrades its rating from Outperform to Market Perform and lowers its price target to $88.00 from $100.00.<\/p>\n

Brilliant Earth Group (BRLT)<\/strong> \u2014 Jefferies Financial Group maintains its Hold rating with a price target of $1.40.<\/p>\n

Bristow Group (VTOL)<\/strong> \u2014 Raymond James maintains its Outperform rating with a price target of $63.00.<\/p>\n

Brookfield Asset Management (BAM)<\/strong> \u2014 JPMorgan maintains its Neutral rating and raises its price target to $58.00 from $55.00.<\/p>\n

Brookfield Renewable Partners (BEP)<\/strong> \u2014 Desjardins upgrades its rating from Hold to Buy.<\/p>\n

Bruker (BRKR)<\/strong> \u2014 Citigroup maintains its Neutral rating and raises its price target to $64.00 from $53.00.<\/p>\n

Bruker (BRKR)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $85.00 from $80.00.<\/p>\n

Cardinal Health (CAH)<\/strong> \u2014 Mizuho sets a price target of $290.00.<\/p>\n

Caris Life Sciences (CAI)<\/strong> \u2014 BTIG Research maintains its Buy rating with a price target of $38.00.<\/p>\n

Caris Life Sciences (CAI)<\/strong> \u2014 TD Cowen maintains its Buy rating and raises its price target to $38.00 from $36.00.<\/p>\n

Caris Life Sciences (CAI)<\/strong> \u2014 UBS sets a price target of $38.00.<\/p>\n

Cars.com (CARS)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $16.00 from $14.00.<\/p>\n

CAVA Group (CAVA)<\/strong> \u2014 BNP Paribas Exane maintains its Neutral rating and lowers its price target to $62.00 from $84.00.<\/p>\n

CAVA Group (CAVA)<\/strong> \u2014 KeyBanc Capital Markets maintains its Overweight rating and lowers its price target to $75.00 from $80.00.<\/p>\n

CAVA Group (CAVA)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and lowers its price target to $80.00 from $85.00.<\/p>\n

CAVA Group (CAVA)<\/strong> \u2014 Sanford C. Bernstein maintains its Outperform rating and lowers its price target to $80.00 from $95.00.<\/p>\n

CAVA Group (CAVA)<\/strong> \u2014 TD Cowen maintains its Buy rating and lowers its price target to $76.00 from $78.00.<\/p>\n

CAVA Group (CAVA)<\/strong> \u2014 Telsey Advisory Group sets a price target of $76.00.<\/p>\n

CDW (CDW)<\/strong> \u2014 Citigroup maintains its Neutral rating and raises its price target to $170.00 from $150.00.<\/p>\n

CDW (CDW)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $195.00 from $170.00.<\/p>\n

CDW (CDW)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $195.00 from $159.00.<\/p>\n

Celanese (CE)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $60.00 from $65.00.<\/p>\n

Cencora (COR)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $405.00 from $388.00.<\/p>\n

Ceragon Networks (CRNT)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $3.50 from $3.00.<\/p>\n

Champion Homes (SKY)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $110.00 from $109.00.<\/p>\n

Champion Homes (SKY)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $99.00 from $94.00.<\/p>\n

Charles River Laboratories International (CRL)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $375.00 from $330.00.<\/p>\n

Charles River Laboratories International (CRL)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $352.00 from $322.00.<\/p>\n

Charles River Laboratories International (CRL)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $387.00 from $357.00.<\/p>\n

Chatham Lodging Trust (CLDT)<\/strong> \u2014 Stifel sets a price target of $16.50.<\/p>\n

Chime Financial (CHYM)<\/strong> \u2014 Goldman Sachs maintains its Buy rating and raises its price target to $43.00 from $38.00.<\/p>\n

Chime Financial (CHYM)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $40.00 from $35.00.<\/p>\n

Chime Financial (CHYM)<\/strong> \u2014 Scotiabank maintains its Sector Outperform rating and raises its price target to $44.00 from $42.00.<\/p>\n

Chime Financial (CHYM)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $34.00 from $31.00.<\/p>\n

Chime Financial (CHYM)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $42.00 from $39.00.<\/p>\n

Choice Hotels International (CHH)<\/strong> \u2014 Wedbush sets a price target of $130.00.<\/p>\n

Cinemark (CNK)<\/strong> \u2014 Morgan Stanley upgrades its rating from Equal Weight to Overweight with a price target of $50.00.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 Citigroup initiates coverage with a Buy rating.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 Compass Point upgrades its rating from Neutral to Buy with a price target of $99.00.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 Deutsche Bank upgrades its rating from Hold to Buy.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 HC Wainwright maintains its Buy rating and lowers its price target to $100.00 from $104.00.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 JPMorgan maintains its Overweight rating and lowers its price target to $100.00 from $110.00.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Market Perform rating and lowers its price target to $90.00 from $105.00.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 Mizuho sets a price target of $46.00.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 Morgan Stanley downgrades its rating from Underweight to Cautious.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $103.00 from $134.00.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 Susquehanna maintains its Neutral rating and lowers its price target to $86.00 from $92.00.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 TD Cowen maintains its Buy rating and lowers its price target to $87.00 from $92.00.<\/p>\n

Circle Internet Group (CRCL)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $101.00 from $115.00.<\/p>\n

Cisco (CSCO)<\/strong> \u2014 Morgan Stanley downgrades its rating from Overweight to Equal Weight and lowers its price target to $120.00 from $135.00.<\/p>\n

Clarivate (CLVT)<\/strong> \u2014 Goldman Sachs maintains its Neutral rating and lowers its price target to $2.30 from $2.60.<\/p>\n

Clarivate (CLVT)<\/strong> \u2014 Jefferies Financial Group maintains its Hold rating with a price target of $2.25.<\/p>\n

CLEAR Secure (YOU)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $75.00 from $55.00.<\/p>\n

CLEAR Secure (YOU)<\/strong> \u2014 Wells Fargo & Company maintains its Underweight rating and raises its price target to $50.00 from $45.00.<\/p>\n

Climb Bio (CLYM)<\/strong> \u2014 Wedbush maintains its Outperform rating with a price target of $27.00.<\/p>\n

Clover Health Investments (CLOV)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $5.50 from $5.00.<\/p>\n

Coca-Cola Europacific Partners (CCEP)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $124.00 from $112.00.<\/p>\n

Collegium Pharmaceutical (COLL)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $44.00 from $46.00.<\/p>\n

Colliers International Group (CIGI)<\/strong> \u2014 National Bank Financial maintains its Outperform rating and raises its price target to $122.00 from $109.00.<\/p>\n

Colliers International Group (CIGI)<\/strong> \u2014 Raymond James maintains its Strong-Buy rating and lowers its price target to $150.00 from $160.00.<\/p>\n

Colliers International Group (CIGI)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and lowers its price target to $140.00 from $155.00.<\/p>\n

Colliers International Group (CIGI)<\/strong> \u2014 Stifel maintains its Buy rating and lowers its price target to $150.00 from $155.00.<\/p>\n

Community Healthcare Trust (CHCT)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and raises its price target to $16.00 from $14.00.<\/p>\n

ConocoPhillips (COP)<\/strong> \u2014 Mizuho sets a price target of $149.00.<\/p>\n

Core Natural Resources (CNR)<\/strong> \u2014 Jefferies Financial Group maintains its Buy rating with a price target of $100.00.<\/p>\n

Corning (GLW)<\/strong> \u2014 Fox Advisors upgrades its rating from Equal Weight to Overweight.<\/p>\n

Corpay (CPAY)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $500.00 from $470.00.<\/p>\n

Corpay (CPAY)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Outperform rating and raises its price target to $525.00 from $470.00.<\/p>\n

Corpay (CPAY)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and raises its price target to $461.00 from $454.00.<\/p>\n

Corpay (CPAY)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $474.00 from $438.00.<\/p>\n

Corpay (CPAY)<\/strong> \u2014 Scotiabank maintains its Sector Outperform rating and raises its price target to $539.00 from $536.00.<\/p>\n

Corpay (CPAY)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $465.00 from $415.00.<\/p>\n

Costco Wholesale (COST)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $1,150.00 from $1,015.00.<\/p>\n

Coupang (CPNG)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $32.00 from $29.00.<\/p>\n

Coupang (CPNG)<\/strong> \u2014 Sanford C. Bernstein maintains its Underperform rating and lowers its price target to $11.00 from $12.00.<\/p>\n

Cricut (CRCT)<\/strong> \u2014 Barclays maintains its Underweight rating and raises its price target to $6.00 from $4.00.<\/p>\n

Criteo (CRTO)<\/strong> \u2014 Citigroup maintains its Buy rating and lowers its price target to $21.00 from $23.00.<\/p>\n

Criteo (CRTO)<\/strong> \u2014 Wedbush maintains its Outperform rating and lowers its price target to $21.00 from $25.00.<\/p>\n

Criteo (CRTO)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $14.00 from $15.00.<\/p>\n

CVS Health (CVS)<\/strong> \u2014 Barclays maintains its Overweight rating and lowers its price target to $107.00 from $108.00.<\/p>\n

CVS Health (CVS)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and lowers its price target to $104.00 from $112.00.<\/p>\n

Cytokinetics (CYTK)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $105.00 from $99.00.<\/p>\n

Cytokinetics (CYTK)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and lowers its price target to $100.00 from $103.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 Barclays maintains its Overweight rating and lowers its price target to $262.00 from $300.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating and lowers its price target to $260.00 from $327.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 Citigroup maintains its Buy rating and lowers its price target to $290.00 from $305.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 DA Davidson maintains its Buy rating and lowers its price target to $275.00 from $315.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and lowers its price target to $270.00 from $320.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 Rosenblatt Securities maintains its Buy rating and lowers its price target to $285.00 from $305.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 Sanford C. Bernstein maintains its Outperform rating and lowers its price target to $273.00 from $350.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 Scotiabank maintains its Sector Outperform rating and lowers its price target to $260.00 from $285.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 TD Cowen maintains its Buy rating and lowers its price target to $275.00 from $300.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 Wedbush maintains its Outperform rating and lowers its price target to $240.00 from $275.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $300.00 from $325.00.<\/p>\n

Dave (DAVE)<\/strong> \u2014 JPMorgan maintains its Overweight rating and lowers its price target to $435.00 from $480.00.<\/p>\n

Deckers Outdoor (DECK)<\/strong> \u2014 Argus maintains its Buy rating and lowers its price target to $102.00 from $128.00.<\/p>\n

Design Therapeutics (DSGN)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and lowers its price target to $19.00 from $20.00.<\/p>\n

Dianthus Therapeutics (DNTH)<\/strong> \u2014 Raymond James maintains its Strong-Buy rating with a price target of $134.00.<\/p>\n

DigitalOcean (DOCN)<\/strong> \u2014 Goldman Sachs maintains its Buy rating and lowers its price target to $156.00 from $178.00.<\/p>\n

Dollar Tree (DLTR)<\/strong> \u2014 Loop Capital downgrades its rating from Buy to Hold with a price target of $140.00.<\/p>\n

Duolingo (DUOL)<\/strong> \u2014 Bank of America maintains its Underperform rating with a price target of $108.00.<\/p>\n

Duolingo (DUOL)<\/strong> \u2014 Truist maintains its Hold rating and raises its price target to $170.00 from $120.00.<\/p>\n

DuPont de Nemours (DD)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $173.00 from $160.00.<\/p>\n

DuPont de Nemours (DD)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $170.00 from $166.00.<\/p>\n

Dutch Bros (BROS)<\/strong> \u2014 BNP Paribas Exane maintains its Outperform rating and lowers its price target to $54.00 from $77.00.<\/p>\n

Dutch Bros (BROS)<\/strong> \u2014 KeyBanc Capital Markets maintains its Overweight rating and lowers its price target to $52.00 from $59.00.<\/p>\n

Dutch Bros (BROS)<\/strong> \u2014 Mizuho sets a price target of $55.00.<\/p>\n

Dutch Bros (BROS)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and lowers its price target to $54.00 from $66.00.<\/p>\n

Dutch Bros (BROS)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and lowers its price target to $38.00 from $46.00.<\/p>\n

Dutch Bros (BROS)<\/strong> \u2014 Stephens maintains its Overweight rating and lowers its price target to $47.00 from $65.00.<\/p>\n

Dutch Bros (BROS)<\/strong> \u2014 TD Cowen maintains its Buy rating and lowers its price target to $50.00 from $55.00.<\/p>\n

Dutch Bros (BROS)<\/strong> \u2014 Telsey Advisory Group sets a price target of $56.00.<\/p>\n

Dutch Bros (BROS)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $50.00 from $55.00.<\/p>\n

e.l.f. Beauty (ELF)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $139.00 from $130.00.<\/p>\n

e.l.f. Beauty (ELF)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $135.00 from $130.00.<\/p>\n

e.l.f. Beauty (ELF)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and raises its price target to $110.00 from $100.00.<\/p>\n

e.l.f. Beauty (ELF)<\/strong> \u2014 Raymond James maintains its Strong-Buy rating with a price target of $132.00.<\/p>\n

e.l.f. Beauty (ELF)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $129.00 from $116.00.<\/p>\n

Eagle Materials (EXP)<\/strong> \u2014 DA Davidson sets a price target of $195.00.<\/p>\n

Eagle Materials (EXP)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $189.00 from $188.00.<\/p>\n

eBay (EBAY)<\/strong> \u2014 Argus maintains its Buy rating and raises its price target to $138.00 from $133.00.<\/p>\n

Edgewise Therapeutics (EWTX)<\/strong> \u2014 Raymond James maintains its Underperform rating with a price target of $85.00.<\/p>\n

Edgewise Therapeutics (EWTX)<\/strong> \u2014 Wedbush maintains its Outperform rating and lowers its price target to $51.00 from $53.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $120.00 from $110.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $115.00 from $110.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $117.00 from $110.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $120.00 from $105.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $112.00 from $101.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 Mizuho sets a price target of $120.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and raises its price target to $115.00 from $101.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $115.00 from $110.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 Robert W. Baird upgrades its rating from Neutral to Outperform with a price target of $116.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 Sanford C. Bernstein maintains its Market Perform rating and raises its price target to $106.00 from $99.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $118.00 from $110.00.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $113.00 from $100.00.<\/p>\n

Emerson Electric (EMR)<\/strong> \u2014 BNP Paribas Exane maintains its Outperform rating and raises its price target to $200.00 from $185.00.<\/p>\n

Emerson Electric (EMR)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $198.00 from $182.00.<\/p>\n

Emerson Electric (EMR)<\/strong> \u2014 KeyBanc Capital Markets maintains its Overweight rating and raises its price target to $200.00 from $170.00.<\/p>\n

Emerson Electric (EMR)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $196.00 from $188.00.<\/p>\n

Emerson Electric (EMR)<\/strong> \u2014 Sanford C. Bernstein maintains its Outperform rating and raises its price target to $196.00 from $186.00.<\/p>\n

Emerson Electric (EMR)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $180.00 from $177.00.<\/p>\n

Encore Capital Group (ECPG)<\/strong> \u2014 Citizens Jmp maintains its Market Outperform rating and raises its price target to $140.00 from $115.00.<\/p>\n

Encore Capital Group (ECPG)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $122.00 from $112.00.<\/p>\n

Enovis (ENOV)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $42.00 from $36.00.<\/p>\n

Enovis (ENOV)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $38.00 from $34.00.<\/p>\n

Envista (NVST)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $29.00 from $27.00.<\/p>\n

EPAM Systems (EPAM)<\/strong> \u2014 Needham & Company LLC maintains its Overweight rating and lowers its price target to $29.00 from $31.00.<\/p>\n

Everus Construction Group (ECG)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and lowers its price target to $170.00 from $200.00.<\/p>\n

Evolent Health (EVH)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $6.00 from $5.00.<\/p>\n

Evolus (EOLS)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $15.00 from $13.00.<\/p>\n

Exelixis (EXEL)<\/strong> \u2014 Leerink Partners maintains its Market Perform rating and raises its price target to $58.00 from $55.00.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 Barclays maintains its Equal Weight rating and lowers its price target to $310.00 from $320.00.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 BTIG Research maintains its Buy rating with a price target of $400.00.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 Cantor Fitzgerald maintains its Neutral rating and raises its price target to $320.00 from $310.00.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 Goldman Sachs maintains its Buy rating with a price target of $320.00.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 JPMorgan maintains its Neutral rating and lowers its price target to $315.00 from $330.00.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and raises its price target to $335.00 from $325.00.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 Wedbush maintains its Outperform rating and lowers its price target to $384.00 from $417.00.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 Wells Fargo & Company maintains its Cautious rating and raises its price target to $278.00 from $275.00.<\/p>\n

Expro Group (XPRO)<\/strong> \u2014 Barclays downgrades its rating from Overweight to Equal Weight and lowers its price target to $14.00 from $19.00.<\/p>\n

FactSet Research Systems (FDS)<\/strong> \u2014 Wells Fargo & Company maintains its Underweight rating and raises its price target to $290.00 from $250.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 Barclays maintains its Overweight rating and lowers its price target to $800.00 from $875.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 JPMorgan maintains its Neutral rating and lowers its price target to $800.00 from $900.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $925.00 from $1,100.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 RBC Capital Markets downgrades its rating from Outperform to Sector Perform and lowers its price target to $770.00 from $1,045.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $650.00 from $735.00.<\/p>\n

Fastly (FSLY)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and lowers its price target to $24.00 from $28.00.<\/p>\n

Fastly (FSLY)<\/strong> \u2014 Raymond James maintains its Outperform rating with a price target of $24.00.<\/p>\n

Fastly (FSLY)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and lowers its price target to $19.00 from $25.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 Bank of America downgrades its rating from Buy to Neutral and lowers its price target to $33.00 from $42.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 Barclays maintains its Equal Weight rating and lowers its price target to $30.00 from $38.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 Citigroup maintains its Neutral rating and lowers its price target to $30.00 from $39.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 Goldman Sachs maintains its Buy rating and lowers its price target to $35.00 from $44.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Outperform rating and lowers its price target to $42.00 from $50.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 National Bank Financial sets a price target of $46.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and lowers its price target to $31.00 from $42.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 RBC Capital Markets downgrades its rating from Outperform to Sector Perform and lowers its price target to $37.00 from $53.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 Susquehanna maintains its Neutral rating and lowers its price target to $32.00 from $37.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 TD Cowen maintains its Buy rating and lowers its price target to $38.00 from $47.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $33.00 from $46.00.<\/p>\n

Figma (FIG)<\/strong> \u2014 JPMorgan maintains its Neutral rating and lowers its price target to $24.00 from $28.00.<\/p>\n

Figma (FIG)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and lowers its price target to $24.00 from $28.00.<\/p>\n

First Industrial Realty Trust (FR)<\/strong> \u2014 Truist maintains its Buy rating and lowers its price target to $62.00 from $73.00.<\/p>\n

First Solar (FSLR)<\/strong> \u2014 William Blair upgrades its rating from Market Perform to Outperform.<\/p>\n

Five Below (FIVE)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $302.00 from $297.00.<\/p>\n

Flutter Entertainment (FLUT)<\/strong> \u2014 Barclays maintains its Overweight rating and lowers its price target to $125.00 from $133.00.<\/p>\n

Flutter Entertainment (FLUT)<\/strong> \u2014 Citizens Jmp maintains its Market Outperform rating and lowers its price target to $116.00 from $129.00.<\/p>\n

Flutter Entertainment (FLUT)<\/strong> \u2014 Susquehanna maintains its Positive rating and raises its price target to $101.00 from $100.00.<\/p>\n

Flutter Entertainment (FLUT)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $86.00 from $112.00.<\/p>\n

Flywire (FLYW)<\/strong> \u2014 Citigroup maintains its Neutral rating and raises its price target to $23.00 from $19.00.<\/p>\n

Freshpet (FRPT)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $78.00 from $76.00.<\/p>\n

Freshpet (FRPT)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $84.00 from $77.00.<\/p>\n

Frontier Group Holdings (ULCC)<\/strong> \u2014 Deutsche Bank upgrades its rating from Hold to Buy and raises its price target to $10.00 from $7.00.<\/p>\n

GATX (GATX)<\/strong> \u2014 Susquehanna maintains its Positive rating and raises its price target to $220.00 from $218.00.<\/p>\n

Genius Sports (GENI)<\/strong> \u2014 BTIG Research maintains its Buy rating and lowers its price target to $8.00 from $10.00.<\/p>\n

GlobalFoundries (GFS)<\/strong> \u2014 Citigroup maintains its Neutral rating and lowers its price target to $46.00 from $58.00.<\/p>\n

GlobalFoundries (GFS)<\/strong> \u2014 JPMorgan maintains its Neutral rating and lowers its price target to $50.00 from $57.00.<\/p>\n

GlobalFoundries (GFS)<\/strong> \u2014 Susquehanna maintains its Positive rating and lowers its price target to $110.00 from $125.00.<\/p>\n

GlobalFoundries (GFS)<\/strong> \u2014 TD Cowen maintains its Buy rating and lowers its price target to $60.00 from $75.00.<\/p>\n

GlobalFoundries (GFS)<\/strong> \u2014 Wedbush maintains its Neutral rating and lowers its price target to $45.00 from $72.00.<\/p>\n

GRAIL (GRAL)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $100.00 from $84.00.<\/p>\n

Grand Canyon Education (LOPE)<\/strong> \u2014 Truist maintains its Buy rating and lowers its price target to $180.00 from $200.00.<\/p>\n

Greenbrier Companies (GBX)<\/strong> \u2014 Susquehanna maintains its Neutral rating and lowers its price target to $45.00 from $52.00.<\/p>\n

Greif (GEF)<\/strong> \u2014 Truist maintains its Hold rating and lowers its price target to $88.00 from $94.00.<\/p>\n

GXO Logistics (GXO)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $66.00 from $65.00.<\/p>\n

GXO Logistics (GXO)<\/strong> \u2014 Goldman Sachs maintains its Buy rating with a price target of $66.00.<\/p>\n

GXO Logistics (GXO)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $73.00 from $68.00.<\/p>\n

GXO Logistics (GXO)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and raises its price target to $65.00 from $61.00.<\/p>\n

GXO Logistics (GXO)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $69.00 from $64.00.<\/p>\n

Haemonetics (HAE)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $142.00 from $130.00.<\/p>\n

Haemonetics (HAE)<\/strong> \u2014 Mizuho sets a price target of $165.00.<\/p>\n

Hamilton Lane (HLNE)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $120.00 from $115.00.<\/p>\n

HCI Group (HCI)<\/strong> \u2014 Citizens Jmp maintains its Market Outperform rating and raises its price target to $280.00 from $265.00.<\/p>\n

HCI Group (HCI)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $245.00 from $235.00.<\/p>\n

Hillman Solutions (HLMN)<\/strong> \u2014 Barclays maintains its Equal Weight rating and lowers its price target to $10.00 from $11.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 Barclays maintains its Equal Weight rating and lowers its price target to $222.00 from $240.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 BTIG Research downgrades its rating from Buy to Neutral.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 Cantor Fitzgerald downgrades its rating from Neutral to Underweight and lowers its price target to $170.00 from $265.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 JPMorgan maintains its Neutral rating and lowers its price target to $224.00 from $240.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 KeyBanc Capital Markets downgrades its rating from Overweight to Sector Weight.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 Morgan Stanley downgrades its rating from Overweight to Equal Weight with a price target of $229.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and lowers its price target to $200.00 from $220.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and lowers its price target to $260.00 from $300.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 TD Cowen maintains its Hold rating and lowers its price target to $215.00 from $260.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 Truist maintains its Buy rating and lowers its price target to $230.00 from $275.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 UBS downgrades its rating from Neutral to Underweight with a price target of $170.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $200.00 from $250.00.<\/p>\n

Huntington Bancshares (HBAN)<\/strong> \u2014 Argus maintains its Buy rating and lowers its price target to $18.00 from $20.00.<\/p>\n

Hut 8 (HUT)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating and lowers its price target to $127.00 from $151.00.<\/p>\n

Hut 8 (HUT)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $101.00 from $138.00.<\/p>\n

Hut 8 (HUT)<\/strong> \u2014 Rosenblatt Securities maintains its Buy rating and lowers its price target to $100.00 from $124.00.<\/p>\n

Hut 8 (HUT)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $148.00 from $175.00.<\/p>\n

IDEAYA Biosciences (IDYA)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $66.00 from $65.00.<\/p>\n

Incyte (INCY)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and lowers its price target to $150.00 from $154.00.<\/p>\n

Innoviva (INVA)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and lowers its price target to $34.00 from $35.00.<\/p>\n

Insulet (PODD)<\/strong> \u2014 Citigroup maintains its Neutral rating and raises its price target to $170.00 from $150.00.<\/p>\n

Insulet (PODD)<\/strong> \u2014 JPMorgan maintains its Neutral rating and raises its price target to $170.00 from $152.00.<\/p>\n

Insulet (PODD)<\/strong> \u2014 Leerink Partners maintains its Market Perform rating and raises its price target to $167.00 from $143.00.<\/p>\n

Insulet (PODD)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $180.00 from $160.00.<\/p>\n

Insulet (PODD)<\/strong> \u2014 Sanford C. Bernstein maintains its Outperform rating and raises its price target to $200.00 from $175.00.<\/p>\n

Insulet (PODD)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $171.00 from $150.00.<\/p>\n

Insulet (PODD)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $172.00 from $144.00.<\/p>\n

International Flavors & Fragrances (IFF)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $105.00 from $100.00.<\/p>\n

International Flavors & Fragrances (IFF)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $95.00 from $92.00.<\/p>\n

International Flavors & Fragrances (IFF)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $95.00 from $91.00.<\/p>\n

Inventiva (IVA)<\/strong> \u2014 HC Wainwright maintains its Buy rating with a price target of $14.00.<\/p>\n

IPG Photonics (IPGP)<\/strong> \u2014 Sanford C. Bernstein maintains its Outperform rating with a price target of $92.00.<\/p>\n

Jack Henry & Associates (JKHY)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $190.00 from $185.00.<\/p>\n

Jack Henry & Associates (JKHY)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Outperform rating and raises its price target to $215.00 from $200.00.<\/p>\n

Jack Henry & Associates (JKHY)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $195.00 from $178.00.<\/p>\n

Jack Henry & Associates (JKHY)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $185.00 from $170.00.<\/p>\n

JELD-WEN (JELD)<\/strong> \u2014 Barclays maintains its Equal Weight rating and lowers its price target to $1.50 from $2.00.<\/p>\n

JetBlue Airways (JBLU)<\/strong> \u2014 Deutsche Bank upgrades its rating from Hold to Buy and raises its price target to $5.50 from $3.00.<\/p>\n

Joby Aviation (JOBY)<\/strong> \u2014 Canaccord Genuity upgrades its rating from Hold to Buy with a price target of $7.00.<\/p>\n

Joby Aviation (JOBY)<\/strong> \u2014 Canaccord Genuity Group upgrades its rating from Hold to Buy and lowers its price target to $7.00 from $11.50.<\/p>\n

Joby Aviation (JOBY)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $10.00 from $15.00.<\/p>\n

Keel Infrastructure (KEEL)<\/strong> \u2014 HC Wainwright maintains its Buy rating and lowers its price target to $3.25 from $4.00.<\/p>\n

Kennametal (KMT)<\/strong> \u2014 JPMorgan maintains its Underweight rating and lowers its price target to $27.00 from $30.00.<\/p>\n

Keurig Dr Pepper (KDP)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $41.00 from $38.00.<\/p>\n

Klaviyo (KVYO)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $23.00 from $22.00.<\/p>\n

Klaviyo (KVYO)<\/strong> \u2014 Goldman Sachs maintains its Neutral rating with a price target of $22.50.<\/p>\n

Klaviyo (KVYO)<\/strong> \u2014 Mizuho sets a price target of $24.00.<\/p>\n

Knife River (KNF)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $59.00 from $58.00.<\/p>\n

Knife River (KNF)<\/strong> \u2014 Stephens maintains its Overweight rating and raises its price target to $70.00 from $65.00.<\/p>\n

Kraft Heinz (KHC)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $26.00 from $24.00.<\/p>\n

Kraft Heinz (KHC)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $24.00 from $23.00.<\/p>\n

Kyndryl (KD)<\/strong> \u2014 Scotiabank maintains its Sector Perform rating and raises its price target to $19.00 from $15.00.<\/p>\n

Kyndryl (KD)<\/strong> \u2014 Susquehanna maintains its Neutral rating and raises its price target to $16.00 from $13.00.<\/p>\n

Labcorp (LH)<\/strong> \u2014 HSBC upgrades its rating from Hold to Buy with a price target of $410.00.<\/p>\n

Labcorp Holdings (LH)<\/strong> \u2014 HSBC Securities upgrades its rating from Hold to Buy with a price target of $410.00.<\/p>\n

LegalZoom.com (LZ)<\/strong> \u2014 Bank of America downgrades its rating from Buy to Underperform.<\/p>\n

LegalZoom.com (LZ)<\/strong> \u2014 JPMorgan maintains its Neutral rating and lowers its price target to $6.00 from $7.00.<\/p>\n

LeMaitre Vascular (LMAT)<\/strong> \u2014 Citizens Jmp maintains its Market Outperform rating and lowers its price target to $110.00 from $127.00.<\/p>\n

LeMaitre Vascular (LMAT)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $86.00 from $94.00.<\/p>\n

LENZ Therapeutics (LENZ)<\/strong> \u2014 Citigroup maintains its Buy rating and lowers its price target to $9.00 from $10.00.<\/p>\n

LifeStance Health Group (LFST)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $20.00 from $18.00.<\/p>\n

Ligand Pharmaceuticals (LGND)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $402.00 from $397.00.<\/p>\n

Light & Wonder (LNWO)<\/strong> \u2014 JPMorgan downgrades its rating from Overweight to Neutral.<\/p>\n

Limbach (LMB)<\/strong> \u2014 JPMorgan maintains its Underweight rating and raises its price target to $55.00 from $50.00.<\/p>\n

LivaNova (LIVN)<\/strong> \u2014 Robert W. Baird maintains its Outperform rating and raises its price target to $111.00 from $95.00.<\/p>\n

Lumen Technologies (LUMN)<\/strong> \u2014 Goldman Sachs maintains its Strong-Buy rating with a price target of $18.00.<\/p>\n

Lumen Technologies (LUMN)<\/strong> \u2014 JPMorgan maintains its Neutral rating and lowers its price target to $6.00 from $7.00.<\/p>\n

Lumen Technologies (LUMN)<\/strong> \u2014 TD Cowen maintains its Hold rating and lowers its price target to $8.00 from $9.00.<\/p>\n

Lumen Technologies (LUMN)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $5.00 from $7.50.<\/p>\n

Lyntris Inc. (LYNX)<\/strong> \u2014 Raymond James upgrades its rating from Outperform to Strong Buy with a price target of $18.00.<\/p>\n

Lyntris Inc. (LYNX)<\/strong> \u2014 Robert W. Baird upgrades its rating from Neutral to Outperform with a price target of $18.00.<\/p>\n

MACOM Technology Solutions (MTSI)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $300.00 from $410.00.<\/p>\n

MACOM Technology Solutions (MTSI)<\/strong> \u2014 Stifel sets a price target of $360.00.<\/p>\n

MACOM Technology Solutions (MTSI)<\/strong> \u2014 Susquehanna maintains its Neutral rating with a price target of $220.00.<\/p>\n

Madison Square Garden Entertainment (MSGE)<\/strong> \u2014 JPMorgan maintains its Neutral rating and raises its price target to $84.00 from $83.00.<\/p>\n

Madison Square Garden Entertainment (MSGE)<\/strong> \u2014 Susquehanna maintains its Positive rating and raises its price target to $93.00 from $92.00.<\/p>\n

Magnite (MGNI)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $30.00 from $27.00.<\/p>\n

Magnite (MGNI)<\/strong> \u2014 Scotiabank maintains its Sector Outperform rating and raises its price target to $30.00 from $27.00.<\/p>\n

Magnite (MGNI)<\/strong> \u2014 Susquehanna maintains its Positive rating and raises its price target to $35.00 from $30.00.<\/p>\n

Magnite (MGNI)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $23.00 from $22.00.<\/p>\n

Manitowoc (MTW)<\/strong> \u2014 Wells Fargo & Company maintains its Underweight rating and raises its price target to $15.00 from $12.00.<\/p>\n

Marathon Petroleum (MPC)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and raises its price target to $466.00 from $462.00.<\/p>\n

Marqeta (MQ)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $21.00 from $19.00.<\/p>\n

Marriott Vacations Worldwide (VAC)<\/strong> \u2014 Barclays maintains its Overweight rating and lowers its price target to $139.00 from $140.00.<\/p>\n

Marriott Vacations Worldwide (VAC)<\/strong> \u2014 JPMorgan maintains its Overweight rating and lowers its price target to $124.00 from $125.00.<\/p>\n

Marriott Vacations Worldwide (VAC)<\/strong> \u2014 Wells Fargo & Company maintains its Underweight rating and lowers its price target to $97.00 from $100.00.<\/p>\n

Martin Marietta Materials (MLM)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $589.00 from $579.00.<\/p>\n

Masco (MAS)<\/strong> \u2014 Argus maintains its Buy rating and raises its price target to $95.00 from $92.00.<\/p>\n

Mastercard (MA)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $735.00 from $674.00.<\/p>\n

Mastercard (MA)<\/strong> \u2014 UBS maintains its Buy rating with a price target of $725.00.<\/p>\n

Matador Resources (MTDR)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $66.00 from $65.00.<\/p>\n

Materion (MTRN)<\/strong> \u2014 KeyBanc Capital Markets maintains its Overweight rating and lowers its price target to $232.00 from $306.00.<\/p>\n

Materion (MTRN)<\/strong> \u2014 Seaport Research Partners upgrades its rating from Neutral to Buy with a price target of $250.00.<\/p>\n

Matson (MATX)<\/strong> \u2014 Stephens maintains its Overweight rating and raises its price target to $300.00 from $270.00.<\/p>\n

Mayville Engineering (MEC)<\/strong> \u2014 Citigroup maintains its Buy rating and lowers its price target to $27.00 from $38.00.<\/p>\n

McDonald’s (MCD)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $305.00 from $295.00.<\/p>\n

McDonald’s (MCD)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $315.00 from $295.00.<\/p>\n

McDonald’s (MCD)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $270.00 from $250.00.<\/p>\n

McDonald’s (MCD)<\/strong> \u2014 KeyBanc Capital Markets maintains its Overweight rating and raises its price target to $307.00 from $280.00.<\/p>\n

McDonald’s (MCD)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $300.00 from $285.00.<\/p>\n

McDonald’s (MCD)<\/strong> \u2014 Sanford C. Bernstein maintains its Market Perform rating and raises its price target to $280.00 from $250.00.<\/p>\n

McDonald’s (MCD)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $300.00 from $270.00.<\/p>\n

McKesson (MCK)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $1,200.00 from $1,070.00.<\/p>\n

McKesson (MCK)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $965.00 from $845.00.<\/p>\n

McKesson (MCK)<\/strong> \u2014 TD Cowen maintains its Buy rating and raises its price target to $1,200.00 from $1,006.00.<\/p>\n

Mechanics Bancorp (MCHB)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Market Perform rating and lowers its price target to $15.50 from $16.00.<\/p>\n

Medline (MDLN)<\/strong> \u2014 BTIG Research maintains its Buy rating with a price target of $55.00.<\/p>\n

Medline (MDLN)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $47.00 from $45.00.<\/p>\n

Medline (MDLN)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $46.00 from $43.00.<\/p>\n

Medline (MDLN)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $49.00 from $43.00.<\/p>\n

Melco Resorts & Entertainment (MLCO)<\/strong> \u2014 Susquehanna downgrades its rating from Positive to Neutral and lowers its price target to $4.00 from $5.00.<\/p>\n

MercadoLibre (MELI)<\/strong> \u2014 BTIG Research maintains its Buy rating and lowers its price target to $2,050.00 from $2,150.00.<\/p>\n

MercadoLibre (MELI)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating and lowers its price target to $2,000.00 from $2,200.00.<\/p>\n

MercadoLibre (MELI)<\/strong> \u2014 Scotiabank maintains its Sector Outperform rating and lowers its price target to $2,300.00 from $2,800.00.<\/p>\n

Meridian (MRBK)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and lowers its price target to $20.00 from $24.00.<\/p>\n

MGE Energy (MGEE)<\/strong> \u2014 Jefferies Financial Group sets a price target of $87.00.<\/p>\n

MGM Resorts International (MGM)<\/strong> \u2014 Argus maintains its Buy rating and lowers its price target to $40.00 from $55.00.<\/p>\n

Mirum Pharmaceuticals (MIRM)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and lowers its price target to $140.00 from $154.00.<\/p>\n

MKS (MKSI)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $300.00 from $390.00.<\/p>\n

MNTN (MNTN)<\/strong> \u2014 Citizens Jmp downgrades its rating from Market Outperform to Market Perform.<\/p>\n

MNTN (MNTN)<\/strong> \u2014 Susquehanna maintains its Positive rating and lowers its price target to $12.00 from $20.00.<\/p>\n

MNTN Inc. (MNTN)<\/strong> \u2014 Citigroup downgrades its rating from Buy to Neutral and lowers its price target to $7.00 from $16.00.<\/p>\n

MNTN Inc. (MNTN)<\/strong> \u2014 Citizens downgrades its rating from Market Outperform to Market Perform.<\/p>\n

MNTN Inc. (MNTN)<\/strong> \u2014 Evercore ISI downgrades its rating from Outperform to In-Line with a price target of $7.00.<\/p>\n

MNTN Inc. (MNTN)<\/strong> \u2014 Raymond James downgrades its rating from Outperform to Market Perform.<\/p>\n

Modine Manufacturing (MOD)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating and lowers its price target to $178.00 from $275.00.<\/p>\n

Modine Manufacturing (MOD)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and lowers its price target to $215.00 from $260.00.<\/p>\n

Motorola Solutions (MSI)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $598.00 from $529.00.<\/p>\n

Motorola Solutions (MSI)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $570.00 from $545.00.<\/p>\n

Motorola Solutions (MSI)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and raises its price target to $533.00 from $531.00.<\/p>\n

Motorola Solutions (MSI)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $555.00 from $550.00.<\/p>\n

Motorola Solutions (MSI)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $570.00 from $520.00.<\/p>\n

Mplx (MPLX)<\/strong> \u2014 Citigroup maintains its Neutral rating and raises its price target to $56.00 from $55.00.<\/p>\n

MYR Group (MYRG)<\/strong> \u2014 KeyBanc Capital Markets upgrades its rating from Sector Weight to Overweight with a price target of $361.00.<\/p>\n

Myriad Genetics (MYGN)<\/strong> \u2014 Leerink Partners maintains its Market Perform rating and raises its price target to $8.00 from $5.00.<\/p>\n

Myriad Genetics (MYGN)<\/strong> \u2014 TD Cowen maintains its Hold rating and raises its price target to $6.75 from $4.50.<\/p>\n

N-able (NABL)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $6.00 from $4.00.<\/p>\n

Navient (NAVI)<\/strong> \u2014 Barclays maintains its Underweight rating and lowers its price target to $6.00 from $7.00.<\/p>\n

Navient (NAVI)<\/strong> \u2014 JPMorgan maintains its Neutral rating and raises its price target to $9.00 from $8.50.<\/p>\n

Navient (NAVI)<\/strong> \u2014 TD Cowen maintains its Sell rating and lowers its price target to $8.00 from $8.50.<\/p>\n

New Era Energy & Digital (NUAI)<\/strong> \u2014 Alliance Global Partners initiates coverage with a Buy rating and a price target of $6.00.<\/p>\n

New York Times (NYT)<\/strong> \u2014 Barclays maintains its Equal Weight rating and raises its price target to $64.00 from $63.00.<\/p>\n

NewAmsterdam Pharma (NAMS)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $46.00 from $48.00.<\/p>\n

Nextpower (NXT)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating and raises its price target to $125.00 from $55.00.<\/p>\n

NiCE (NICE)<\/strong> \u2014 Citizens Jmp maintains its Market Outperform rating and lowers its price target to $158.00 from $170.00.<\/p>\n

NiCE (NICE)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and lowers its price target to $130.00 from $145.00.<\/p>\n

Nike (NKE)<\/strong> \u2014 Truist downgrades its rating from Hold to Sell with a price target of $29.00.<\/p>\n

NNN REIT (NNN)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $43.00 from $42.00.<\/p>\n

Nomad Foods (NOMD)<\/strong> \u2014 BTIG Research maintains its Buy rating with a price target of $15.00.<\/p>\n

NOV (NOV)<\/strong> \u2014 Citigroup maintains its Neutral rating and lowers its price target to $20.00 from $21.00.<\/p>\n

Nova (NVMI)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $420.00 from $570.00.<\/p>\n

Nuvation Bio (NUVB)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and lowers its price target to $17.00 from $20.00.<\/p>\n

Ovintiv (OVV)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $90.00 from $77.00.<\/p>\n

Ovintiv (OVV)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $81.00 from $82.00.<\/p>\n

Owens Corning (OC)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and lowers its price target to $119.00 from $127.00.<\/p>\n

Owens Corning (OC)<\/strong> \u2014 Truist maintains its Hold rating and raises its price target to $120.00 from $115.00.<\/p>\n

Owens Corning (OC)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $133.00 from $125.00.<\/p>\n

Pacific Biosciences of California (PACB)<\/strong> \u2014 Barclays maintains its Underweight rating and raises its price target to $2.00 from $1.25.<\/p>\n

Pacific Biosciences of California (PACB)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and raises its price target to $3.00 from $2.00.<\/p>\n

PACS Group (PACS)<\/strong> \u2014 Stephens maintains its Overweight rating and raises its price target to $64.00 from $60.00.<\/p>\n

PACS Group (PACS)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $65.00 from $62.00.<\/p>\n

PACS Group (PACS)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $67.00 from $60.00.<\/p>\n

PagSeguro Digital (PAGS)<\/strong> \u2014 UBS downgrades its rating from Buy to Neutral and lowers its price target to $8.00 from $13.00.<\/p>\n

Palomar (PLMR)<\/strong> \u2014 Truist sets a price target of $175.00.<\/p>\n

Papa John’s International (PZZA)<\/strong> \u2014 Stephens maintains its Equal Weight rating with a price target of $19.00.<\/p>\n

Pattern Group (PTRN)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $29.00 from $27.00.<\/p>\n

Pattern Group (PTRN)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $32.00 from $29.00.<\/p>\n

Paycom Software (PAYC)<\/strong> \u2014 BTIG Research downgrades its rating from Buy to Neutral.<\/p>\n

Paycom Software (PAYC)<\/strong> \u2014 JPMorgan maintains its Neutral rating and raises its price target to $265.00 from $264.00.<\/p>\n

Paycom Software (PAYC)<\/strong> \u2014 KeyBanc Capital Markets maintains its Overweight rating and raises its price target to $297.00 from $295.00.<\/p>\n

PayPay (PAYP)<\/strong> \u2014 Citigroup maintains its Neutral rating and lowers its price target to $17.00 from $18.00.<\/p>\n

The Pennant Group (PNTG)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and raises its price target to $50.00 from $47.00.<\/p>\n

People Incorporated Common Stock (PPLI)<\/strong> \u2014 UBS maintains its Neutral rating and lowers its price target to $45.00 from $56.00.<\/p>\n

Performance Food Group (PFGC)<\/strong> \u2014 Sanford C. Bernstein maintains its Outperform rating and raises its price target to $135.00 from $130.00.<\/p>\n

Performance Food Group (PFGC)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $133.00 from $130.00.<\/p>\n

Pfizer (PFE)<\/strong> \u2014 Guggenheim maintains its Buy rating and raises its price target to $33.00 from $31.00.<\/p>\n

Phillips Edison & Company, Inc. (PECO)<\/strong> \u2014 JPMorgan maintains its Neutral rating and raises its price target to $43.00 from $41.00.<\/p>\n

Planet Fitness (PLNT)<\/strong> \u2014 Raymond James maintains its Strong-Buy rating with a price target of $72.00.<\/p>\n

Power Integrations (POWI)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $65.00 from $80.00.<\/p>\n

Power Integrations (POWI)<\/strong> \u2014 Stifel sets a price target of $62.00.<\/p>\n

Power Integrations (POWI)<\/strong> \u2014 Susquehanna maintains its Positive rating and lowers its price target to $55.00 from $70.00.<\/p>\n

Power Integrations (POWI)<\/strong> \u2014 Williams Trading sets a price target of $65.00.<\/p>\n

Precigen (PGEN)<\/strong> \u2014 Citizens Jmp maintains its Market Outperform rating and raises its price target to $12.00 from $11.00.<\/p>\n

Precigen (PGEN)<\/strong> \u2014 Raymond James sets a price target of $12.00.<\/p>\n

Primoris Services (PRIM)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $110.00 from $172.00.<\/p>\n

Primoris Services (PRIM)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and lowers its price target to $115.00 from $135.00.<\/p>\n

PROCEPT BioRobotics (PRCT)<\/strong> \u2014 Leerink Partners maintains its Market Perform rating and raises its price target to $22.00 from $20.00.<\/p>\n

PROCEPT BioRobotics (PRCT)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $21.00 from $20.00.<\/p>\n

Procore Technologies (PCOR)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $85.00 from $62.00.<\/p>\n

Procore Technologies (PCOR)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $90.00 from $66.00.<\/p>\n

Procore Technologies (PCOR)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating and raises its price target to $90.00 from $70.00.<\/p>\n

Procore Technologies (PCOR)<\/strong> \u2014 Citizens Jmp maintains its Market Outperform rating and raises its price target to $91.00 from $77.00.<\/p>\n

Procore Technologies (PCOR)<\/strong> \u2014 Goldman Sachs maintains its Buy rating and raises its price target to $90.00 from $70.00.<\/p>\n

Procore Technologies (PCOR)<\/strong> \u2014 Guggenheim maintains its Buy rating and raises its price target to $85.00 from $68.00.<\/p>\n

Procore Technologies (PCOR)<\/strong> \u2014 Loop Capital upgrades its rating from Hold to Buy with a price target of $93.00.<\/p>\n

Procore Technologies (PCOR)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and raises its price target to $90.00 from $68.00.<\/p>\n

Procore Technologies (PCOR)<\/strong> \u2014 Truist sets a price target of $91.00.<\/p>\n

Procore Technologies (PCOR)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $95.00 from $80.00.<\/p>\n

Progyny (PGNY)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating and raises its price target to $35.00 from $31.00.<\/p>\n

Progyny (PGNY)<\/strong> \u2014 Citizens Jmp maintains its Market Outperform rating and raises its price target to $38.00 from $33.00.<\/p>\n

Progyny (PGNY)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $38.00 from $37.00.<\/p>\n

Progyny (PGNY)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $38.00 from $37.00.<\/p>\n

Prudential Financial (PRU)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and raises its price target to $133.00 from $120.00.<\/p>\n

PureCycle Technologies (PCT)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating and lowers its price target to $8.00 from $12.00.<\/p>\n

Pursuit Attractions and Hospitality (PRSU)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and raises its price target to $65.00 from $58.00.<\/p>\n

Pyxis Oncology (PYXS)<\/strong> \u2014 Stifel sets a price target of $5.00.<\/p>\n

Qualcomm (QCOM)<\/strong> \u2014 Barclays maintains its Underweight rating and lowers its price target to $150.00 from $180.00.<\/p>\n

Qualcomm (QCOM)<\/strong> \u2014 JPMorgan maintains its Neutral rating and lowers its price target to $200.00 from $215.00.<\/p>\n

Qualcomm (QCOM)<\/strong> \u2014 Robert W. Baird sets a price target of $320.00.<\/p>\n

Qualcomm (QCOM)<\/strong> \u2014 Rosenblatt Securities maintains its Buy rating and lowers its price target to $205.00 from $235.00.<\/p>\n

Qualcomm (QCOM)<\/strong> \u2014 Susquehanna maintains its Neutral rating and lowers its price target to $165.00 from $185.00.<\/p>\n

Qualcomm (QCOM)<\/strong> \u2014 TD Cowen maintains its Buy rating and lowers its price target to $185.00 from $200.00.<\/p>\n

Qualcomm (QCOM)<\/strong> \u2014 UBS maintains its Neutral rating and lowers its price target to $180.00 from $185.00.<\/p>\n

Ralliant (RAL)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $88.00 from $85.00.<\/p>\n

Ralliant (RAL)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $73.00 from $72.00.<\/p>\n

Ralliant (RAL)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $88.00 from $82.00.<\/p>\n

Rapid7 (RPD)<\/strong> \u2014 Barclays maintains its Underweight rating and raises its price target to $14.00 from $12.00.<\/p>\n

Rapid7 (RPD)<\/strong> \u2014 Citigroup maintains its Neutral rating and raises its price target to $16.00 from $13.00.<\/p>\n

Rapid7 (RPD)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and raises its price target to $20.00 from $12.00.<\/p>\n

Rapid7 (RPD)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $16.00 from $12.00.<\/p>\n

Rapid7 (RPD)<\/strong> \u2014 Scotiabank maintains its Sector Perform rating and raises its price target to $14.50 from $10.15.<\/p>\n

Rapid7 (RPD)<\/strong> \u2014 Truist maintains its Hold rating and raises its price target to $15.00 from $10.00.<\/p>\n

Rapid7 (RPD)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $19.00 from $12.00.<\/p>\n

Rapport Therapeutics (RAPP)<\/strong> \u2014 Guggenheim maintains its Buy rating and lowers its price target to $66.00 from $70.00.<\/p>\n

Rapport Therapeutics (RAPP)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $47.00 from $50.00.<\/p>\n

Real REMAX Group (REAX)<\/strong> \u2014 BTIG Research maintains its Buy rating and lowers its price target to $25.00 from $35.00.<\/p>\n

Realty Income (O)<\/strong> \u2014 Cantor Fitzgerald maintains its Neutral rating and lowers its price target to $63.00 from $68.00.<\/p>\n

Red Rock Resorts (RRR)<\/strong> \u2014 Citigroup maintains its Buy rating and lowers its price target to $65.00 from $69.00.<\/p>\n

Red Rock Resorts (RRR)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $65.00 from $78.00.<\/p>\n

Red Violet (RDVT)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $100.00 from $90.00.<\/p>\n

Revolution Medicines (RVMD)<\/strong> \u2014 Guggenheim maintains its Buy rating and raises its price target to $298.00 from $275.00.<\/p>\n

Revolution Medicines (RVMD)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and raises its price target to $222.00 from $210.00.<\/p>\n

Revolution Medicines (RVMD)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $321.00 from $260.00.<\/p>\n

Revolution Medicines (RVMD)<\/strong> \u2014 TD Cowen maintains its Buy rating and raises its price target to $270.00 from $250.00.<\/p>\n

Revolution Medicines (RVMD)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $261.00 from $241.00.<\/p>\n

Reynolds Consumer Products (REYN)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $27.00 from $24.00.<\/p>\n

Rhythm Pharmaceuticals (RYTM)<\/strong> \u2014 Guggenheim maintains its Buy rating and raises its price target to $147.00 from $143.00.<\/p>\n

Ridgepost Capital (RPC)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $12.00 from $11.00.<\/p>\n

Ridgepost Capital (RPC)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $15.00 from $14.00.<\/p>\n

Ridgepost Capital (RPC)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and lowers its price target to $14.00 from $15.00.<\/p>\n

Root (ROOT)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Outperform rating and lowers its price target to $70.00 from $75.00.<\/p>\n

Root (ROOT)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $53.00 from $47.00.<\/p>\n

Royalty Pharma (RPRX)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $78.00 from $70.00.<\/p>\n

Schrodinger (SDGR)<\/strong> \u2014 TD Cowen maintains its Buy rating and raises its price target to $36.00 from $31.00.<\/p>\n

Scotts Miracle-Gro (SMG)<\/strong> \u2014 JPMorgan maintains its Neutral rating and lowers its price target to $67.00 from $70.00.<\/p>\n

Scotts Miracle-Gro (SMG)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $77.00 from $70.00.<\/p>\n

Scotts Miracle-Gro (SMG)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $76.00 from $71.00.<\/p>\n

Seacoast Banking Corporation of Florida (SBCF)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Outperform rating and raises its price target to $38.00 from $37.00.<\/p>\n

Seaport Therapeutics (SPTX)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $41.00 from $40.00.<\/p>\n

Sezzle (SEZL)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $220.00 from $172.00.<\/p>\n

Sezzle (SEZL)<\/strong> \u2014 TD Cowen maintains its Buy rating and raises its price target to $200.00 from $160.00.<\/p>\n

SharkNinja (SN)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $250.00 from $245.00.<\/p>\n

SharkNinja (SN)<\/strong> \u2014 JPMorgan maintains its Overweight rating and raises its price target to $243.00 from $223.00.<\/p>\n

Shoals Technologies Group (SHLS)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating and raises its price target to $12.00 from $11.00.<\/p>\n

Shopify (SHOP)<\/strong> \u2014 Argus maintains its Buy rating with a price target of $180.00.<\/p>\n

Sight Sciences (SGHT)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and raises its price target to $12.00 from $9.00.<\/p>\n

Silvaco Group (SVCO)<\/strong> \u2014 TD Cowen maintains its Buy rating and lowers its price target to $12.00 from $15.00.<\/p>\n

SiTime (SITM)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $600.00 from $900.00.<\/p>\n

Six Flags Entertainment (FUN)<\/strong> \u2014 Stifel sets a price target of $15.00.<\/p>\n

Skyworks (SWKS)<\/strong> \u2014 Barclays downgrades its rating from Overweight to Equal Weight and raises its price target to $79.00 from $70.00.<\/p>\n

SM Energy (SM)<\/strong> \u2014 Susquehanna sets a price target of $33.00.<\/p>\n

SM Energy (SM)<\/strong> \u2014 Truist maintains its Buy rating and lowers its price target to $47.00 from $48.00.<\/p>\n

SM Energy (SM)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $46.00 from $47.00.<\/p>\n

Snap (SNAP)<\/strong> \u2014 Barclays maintains its Overweight rating and lowers its price target to $8.00 from $16.00.<\/p>\n

Snap (SNAP)<\/strong> \u2014 Cantor Fitzgerald maintains its Neutral rating and lowers its price target to $5.00 from $6.00.<\/p>\n

Snap (SNAP)<\/strong> \u2014 JPMorgan maintains its Underweight rating and lowers its price target to $5.00 from $6.00.<\/p>\n

Snap (SNAP)<\/strong> \u2014 Raymond James maintains its Outperform rating with a price target of $7.00.<\/p>\n

SolarEdge Technologies (SEDG)<\/strong> \u2014 Citigroup maintains its Sell rating and lowers its price target to $24.00 from $30.00.<\/p>\n

SolarEdge Technologies (SEDG)<\/strong> \u2014 Goldman Sachs maintains its Sell rating and lowers its price target to $25.00 from $29.00.<\/p>\n

SolarEdge Technologies (SEDG)<\/strong> \u2014 JPMorgan maintains its Neutral rating and lowers its price target to $31.00 from $38.00.<\/p>\n

SolarEdge Technologies (SEDG)<\/strong> \u2014 Susquehanna maintains its Neutral rating and lowers its price target to $31.00 from $32.00.<\/p>\n

Sony (SONY)<\/strong> \u2014 Sanford C. Bernstein maintains its Market Perform rating with a price target of $26.00.<\/p>\n

South Bow (SOBO)<\/strong> \u2014 Barclays maintains its Underweight rating and raises its price target to $34.00 from $33.00.<\/p>\n

SpaceX (SPCX)<\/strong> \u2014 China Renaissance initiates coverage with a Buy rating and a price target of $194.20.<\/p>\n

Sprout Social (SPT)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $14.00 from $12.00.<\/p>\n

Sprouts Farmers Market (SFM)<\/strong> \u2014 Northcoast downgrades its rating from Buy to Neutral.<\/p>\n

Sprouts Farmers Market (SFM)<\/strong> \u2014 Northcoast Research downgrades its rating from Buy to Neutral.<\/p>\n

STAAR Surgical (STAA)<\/strong> \u2014 UBS sets a price target of $34.00.<\/p>\n

Stanley Black & Decker (SWK)<\/strong> \u2014 Citigroup maintains its Buy rating and raises its price target to $140.00 from $107.00.<\/p>\n

Stanley Black & Decker (SWK)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $115.00 from $90.00.<\/p>\n

Steven Madden (SHOO)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $45.00 from $52.00.<\/p>\n

StoneCo (STNE)<\/strong> \u2014 UBS downgrades its rating from Buy to Neutral and lowers its price target to $8.50 from $15.00.<\/p>\n

Sun Life (SLF)<\/strong> \u2014 National Bank Financial downgrades its rating from Outperform to Sector Perform.<\/p>\n

Sunrun (RUN)<\/strong> \u2014 Citigroup maintains its Buy rating and lowers its price target to $13.00 from $14.00.<\/p>\n

Sunrun (RUN)<\/strong> \u2014 JPMorgan maintains its Overweight rating and lowers its price target to $11.00 from $12.00.<\/p>\n

Sysco (SYY)<\/strong> \u2014 Citigroup maintains its Neutral rating and lowers its price target to $84.00 from $87.00.<\/p>\n

Taboola (TBLA)<\/strong> \u2014 Rosenblatt downgrades its rating from Buy to Neutral with a price target of $2.80.<\/p>\n

Taboola.com (TBLA)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $4.00 from $5.50.<\/p>\n

Taboola.com (TBLA)<\/strong> \u2014 Rosenblatt Securities downgrades its rating from Buy to Neutral with a price target of $2.80.<\/p>\n

Targa Resources (TRGP)<\/strong> \u2014 Raymond James sets a price target of $344.00.<\/p>\n

Tarsus Pharmaceuticals (TARS)<\/strong> \u2014 Guggenheim maintains its Buy rating and raises its price target to $97.00 from $89.00.<\/p>\n

TaskUs (TASK)<\/strong> \u2014 Goldman Sachs maintains its Sell rating and raises its price target to $8.00 from $7.00.<\/p>\n

Teads (TEAD)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $0.40 from $1.00.<\/p>\n

Teladoc Health (TDOC)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $8.00 from $6.00.<\/p>\n

Tennant (TNC)<\/strong> \u2014 Subscribe to MarketBeat All Access to unlock brokerage rankings upgrades its rating from Hold to Buy and raises its price target to $85.00 from $77.00.<\/p>\n

Tennant (TNC)<\/strong> \u2014 UBS sets a price target of $85.00.<\/p>\n

Ternium (TX)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $52.00 from $56.00.<\/p>\n

Teva Pharmaceutical Industries (TEVA)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $52.00 from $45.00.<\/p>\n

thredUP (TDUP)<\/strong> \u2014 Northland Capital downgrades its rating from Outperform to Market Perform with a price target of $2.00.<\/p>\n

ThredUp (TDUP)<\/strong> \u2014 Northland Securities downgrades its rating from Outperform to Market Perform with a price target of $2.00.<\/p>\n

ThredUp (TDUP)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $3.00 from $8.00.<\/p>\n

thredUP (TDUP)<\/strong> \u2014 William Blair downgrades its rating from Outperform to Market Perform.<\/p>\n

Timken (TKR)<\/strong> \u2014 Citigroup maintains its Buy rating and lowers its price target to $125.00 from $140.00.<\/p>\n

Timken (TKR)<\/strong> \u2014 Goldman Sachs maintains its Neutral rating with a price target of $126.00.<\/p>\n

TKO Group (TKO)<\/strong> \u2014 Guggenheim maintains its Buy rating and raises its price target to $240.00 from $228.00.<\/p>\n

TKO Group (TKO)<\/strong> \u2014 Susquehanna maintains its Positive rating and lowers its price target to $223.00 from $224.00.<\/p>\n

Traeger (COOK)<\/strong> \u2014 Telsey Advisory Group sets a price target of $58.00.<\/p>\n

Travere Therapeutics (TVTX)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and lowers its price target to $67.00 from $78.00.<\/p>\n

Trex (TREX)<\/strong> \u2014 Bank of America upgrades its rating from Underperform to Buy and raises its price target to $65.00 from $46.00.<\/p>\n

Trex (TREX)<\/strong> \u2014 Barclays maintains its Underweight rating and raises its price target to $46.00 from $42.00.<\/p>\n

Trex (TREX)<\/strong> \u2014 Citigroup maintains its Neutral rating and raises its price target to $59.00 from $52.00.<\/p>\n

Trex (TREX)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $75.00 from $60.00.<\/p>\n

Trimble (TRMB)<\/strong> \u2014 JPMorgan maintains its Overweight rating and lowers its price target to $73.00 from $75.00.<\/p>\n

Trimble (TRMB)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and lowers its price target to $73.00 from $80.00.<\/p>\n

Trimble (TRMB)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $60.00 from $61.00.<\/p>\n

Trinity Capital (TRIN)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Market Perform rating and raises its price target to $18.00 from $16.50.<\/p>\n

Trinity Capital (TRIN)<\/strong> \u2014 Wells Fargo & Company maintains its Underweight rating and raises its price target to $16.00 from $15.00.<\/p>\n

Trinity Industries (TRN)<\/strong> \u2014 Susquehanna maintains its Neutral rating and raises its price target to $34.00 from $32.00.<\/p>\n

TriplePoint Venture Growth BDC (TPVG)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Market Perform rating and lowers its price target to $5.00 from $5.50.<\/p>\n

Trivago N.V. ADS (TRVG)<\/strong> \u2014 Susquehanna maintains its Neutral rating and lowers its price target to $4.00 from $5.50.<\/p>\n

Tutor Perini (TPC)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $107.00 from $105.00.<\/p>\n

TWFG (TWFG)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Market Perform rating and raises its price target to $30.00 from $28.00.<\/p>\n

TWFG (TWFG)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and raises its price target to $34.00 from $31.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Barclays maintains its Overweight rating and lowers its price target to $100.00 from $106.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Canaccord Genuity Group maintains its Hold rating and lowers its price target to $70.00 from $72.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating with a price target of $90.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Goldman Sachs maintains its Buy rating and lowers its price target to $110.00 from $115.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Guggenheim maintains its Buy rating with a price target of $125.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 KeyBanc Capital Markets maintains its Overweight rating and lowers its price target to $95.00 from $105.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $100.00 from $109.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Rosenblatt Securities maintains its Buy rating and lowers its price target to $95.00 from $100.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Sanford C. Bernstein maintains its Outperform rating and lowers its price target to $90.00 from $95.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Wedbush maintains its Outperform rating with a price target of $91.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and lowers its price target to $87.00 from $92.00.<\/p>\n

Ultragenyx Pharmaceutical (RARE)<\/strong> \u2014 Barclays maintains its Overweight rating and lowers its price target to $32.00 from $35.00.<\/p>\n

Ultragenyx Pharmaceutical (RARE)<\/strong> \u2014 Citigroup maintains its Buy rating and lowers its price target to $22.00 from $32.00.<\/p>\n

Union Pacific (UNP)<\/strong> \u2014 Robert W. Baird downgrades its rating from Outperform to Neutral and lowers its price target to $310.00 from $344.00.<\/p>\n

United Fire Group (UFCS)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and lowers its price target to $58.00 from $60.00.<\/p>\n

United Therapeutics (UTHR)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $725.00 from $697.00.<\/p>\n

United Therapeutics (UTHR)<\/strong> \u2014 TD Cowen maintains its Buy rating and raises its price target to $700.00 from $675.00.<\/p>\n

United Therapeutics (UTHR)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $703.00 from $700.00.<\/p>\n

Unity Software (U)<\/strong> \u2014 BTIG Research maintains its Buy rating and raises its price target to $60.00 from $53.00.<\/p>\n

Unity Software (U)<\/strong> \u2014 Raymond James maintains its Outperform rating with a price target of $60.00.<\/p>\n

Unum Group (UNM)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Outperform rating and lowers its price target to $97.00 from $108.00.<\/p>\n

Unum Group (UNM)<\/strong> \u2014 Truist maintains its Buy rating and lowers its price target to $85.00 from $96.00.<\/p>\n

Upland Software (UPLD)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $6.00 from $10.00.<\/p>\n

Urogen Pharma (URGN)<\/strong> \u2014 Guggenheim maintains its Buy rating and lowers its price target to $56.00 from $58.00.<\/p>\n

Urogen Pharma (URGN)<\/strong> \u2014 Oppenheimer sets a price target of $60.00.<\/p>\n

US Foods (USFD)<\/strong> \u2014 TD Cowen maintains its Buy rating and raises its price target to $125.00 from $119.00.<\/p>\n

V.F. (VFC)<\/strong> \u2014 Barclays maintains its Overweight rating and raises its price target to $28.00 from $24.00.<\/p>\n

Varonis Systems (VRNS)<\/strong> \u2014 Susquehanna downgrades its rating from Positive to Neutral and lowers its price target to $49.75 from $55.00.<\/p>\n

Veracyte (VCYT)<\/strong> \u2014 Leerink Partners downgrades its rating from Outperform to Market Perform and lowers its price target to $35.00 from $55.00.<\/p>\n

Veracyte (VCYT)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $46.00 from $69.00.<\/p>\n

Versigent (VGNT)<\/strong> \u2014 BNP Paribas Exane maintains its Outperform rating and lowers its price target to $54.00 from $55.00.<\/p>\n

Versigent (VGNT)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and lowers its price target to $52.00 from $53.00.<\/p>\n

Versigent (VGNT)<\/strong> \u2014 TD Cowen maintains its Buy rating and raises its price target to $59.00 from $58.00.<\/p>\n

Vertex (VERX)<\/strong> \u2014 DA Davidson sets a price target of $16.00.<\/p>\n

Vertex (VERX)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $30.00 from $20.00.<\/p>\n

Vertex (VERX)<\/strong> \u2014 Piper Sandler maintains its Neutral rating and raises its price target to $20.00 from $16.00.<\/p>\n

Viavi Solutions (VIAV)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $53.00 from $60.00.<\/p>\n

VICI Properties (VICI)<\/strong> \u2014 Citigroup maintains its Buy rating and lowers its price target to $30.00 from $36.00.<\/p>\n

Vir Biotechnology (VIR)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $20.00 from $18.00.<\/p>\n

Viridian Therapeutics (VRDN)<\/strong> \u2014 HC Wainwright maintains its Buy rating and raises its price target to $40.00 from $22.00.<\/p>\n

Viridian Therapeutics (VRDN)<\/strong> \u2014 Leerink Partners maintains its Outperform rating and raises its price target to $54.00 from $50.00.<\/p>\n

Viridian Therapeutics (VRDN)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $41.00 from $38.00.<\/p>\n

Viridian Therapeutics (VRDN)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $42.00 from $39.00.<\/p>\n

Viridian Therapeutics (VRDN)<\/strong> \u2014 Wedbush maintains its Outperform rating and raises its price target to $42.00 from $41.00.<\/p>\n

Viridian Therapeutics (VRDN)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $34.00 from $31.00.<\/p>\n

Visa (V)<\/strong> \u2014 Truist maintains its Buy rating and raises its price target to $470.00 from $443.00.<\/p>\n

Vishay Intertechnology (VSH)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $38.00 from $45.00.<\/p>\n

Vishay Intertechnology (VSH)<\/strong> \u2014 Williams Trading sets a price target of $38.00.<\/p>\n

Vistra (VST)<\/strong> \u2014 BMO Capital Markets maintains its Outperform rating and lowers its price target to $188.00 from $210.00.<\/p>\n

W.W. Grainger (GWW)<\/strong> \u2014 Oppenheimer maintains its Outperform rating and raises its price target to $1,645.00 from $1,375.00.<\/p>\n

W.W. Grainger (GWW)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $1,582.00 from $1,427.00.<\/p>\n

W.W. Grainger (GWW)<\/strong> \u2014 Sanford C. Bernstein maintains its Market Perform rating with a price target of $1,400.00.<\/p>\n

W.W. Grainger (GWW)<\/strong> \u2014 Stephens maintains its Equal Weight rating and raises its price target to $1,380.00 from $1,355.00.<\/p>\n

Wayfair (W)<\/strong> \u2014 BNP Paribas Exane maintains its Neutral rating and raises its price target to $134.00 from $108.00.<\/p>\n

Wayfair (W)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and raises its price target to $145.00 from $133.00.<\/p>\n

Wayfair (W)<\/strong> \u2014 RBC Capital Markets maintains its Sector Perform rating and raises its price target to $128.00 from $96.00.<\/p>\n

Wayfair (W)<\/strong> \u2014 Sanford C. Bernstein maintains its Outperform rating and raises its price target to $140.00 from $125.00.<\/p>\n

Wayfair (W)<\/strong> \u2014 TD Cowen maintains its Hold rating and raises its price target to $114.00 from $110.00.<\/p>\n

Wayfair (W)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $165.00 from $156.00.<\/p>\n

Wayfair (W)<\/strong> \u2014 Wedbush maintains its Neutral rating and raises its price target to $138.00 from $125.00.<\/p>\n

Wayfair (W)<\/strong> \u2014 Wells Fargo & Company maintains its Overweight rating and raises its price target to $140.00 from $130.00.<\/p>\n

Western Union (WU)<\/strong> \u2014 UBS maintains its Neutral rating and raises its price target to $6.50 from $6.25.<\/p>\n

Willis Towers Watson Public (WTW)<\/strong> \u2014 Keefe, Bruyette & Woods maintains its Outperform rating and raises its price target to $397.00 from $360.00.<\/p>\n

Wolfspeed (WOLF)<\/strong> \u2014 TD Cowen maintains its Hold rating and lowers its price target to $23.00 from $25.00.<\/p>\n

Xencor (XNCR)<\/strong> \u2014 Cantor Fitzgerald maintains its Overweight rating with a price target of $70.00.<\/p>\n

Yum! Brands (YUM)<\/strong> \u2014 Guggenheim maintains its Buy rating and raises its price target to $180.00 from $155.00.<\/p>\n

Zillow Group (ZG)<\/strong> \u2014 Cantor Fitzgerald maintains its Neutral rating and lowers its price target to $26.00 from $32.00.<\/p>\n

Zillow Group (ZG)<\/strong> \u2014 Citizens Jmp maintains its Market Outperform rating and lowers its price target to $40.00 from $46.00.<\/p>\n

Zillow Group (ZG)<\/strong> \u2014 Evercore ISI maintains its Reduce rating with a price target of $35.00.<\/p>\n

Zillow Group (ZG)<\/strong> \u2014 Piper Sandler maintains its Overweight rating and lowers its price target to $39.00 from $46.00.<\/p>\n

Zillow Group (ZG)<\/strong> \u2014 Sanford C. Bernstein maintains its Market Perform rating and lowers its price target to $34.00 from $38.00.<\/p>\n

Zillow Group (ZG)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and lowers its price target to $30.00 from $31.00.<\/p>\n

Zimmer Biomet (ZBH)<\/strong> \u2014 Citigroup maintains its Neutral rating and raises its price target to $117.00 from $99.00.<\/p>\n

Zimmer Biomet (ZBH)<\/strong> \u2014 JPMorgan maintains its Neutral rating and raises its price target to $120.00 from $117.00.<\/p>\n

Zimmer Biomet (ZBH)<\/strong> \u2014 RBC Capital Markets maintains its Outperform rating and raises its price target to $125.00 from $110.00.<\/p>\n

Zimmer Biomet (ZBH)<\/strong> \u2014 Sanford C. Bernstein maintains its Market Perform rating and raises its price target to $107.00 from $93.00.<\/p>\n

Zimmer Biomet (ZBH)<\/strong> \u2014 Truist sets a price target of $114.00.<\/p>\n

Zimmer Biomet (ZBH)<\/strong> \u2014 UBS maintains its Buy rating and raises its price target to $130.00 from $120.00.<\/p>\n

Zimmer Biomet (ZBH)<\/strong> \u2014 Wells Fargo & Company maintains its Equal Weight rating and raises its price target to $113.00 from $103.00.<\/p>\n

ZoomInfo (GTM)<\/strong> \u2014 Piper Sandler upgrades its rating from Underweight to Neutral and raises its price target to $4.00 from $3.00.<\/p>\n

ZoomInfo Technologies (GTM)<\/strong> \u2014 Needham & Company LLC maintains its Buy rating and lowers its price target to $8.00 from $15.00.<\/p>\n

ZoomInfo Technologies (GTM)<\/strong> \u2014 RBC Capital Markets maintains its Underperform rating and raises its price target to $3.50 from $3.00.<\/p>\n","protected":false},"excerpt":{"rendered":"

Analyst Ratings (USA) Wall Street analyst outlook fot today remains mixed and increasingly cautious, with significant downgrades across technology, software, financial services, consumer discretionary,…<\/p>\n","protected":false},"author":3,"featured_media":76865,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-76855","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"\nAmerican Analyst Updates: Nov 5th, 2026 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"American Analyst Updates: Nov 5th, 2026\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings (USA) Wall Street analyst outlook fot today remains mixed and increasingly cautious, with significant downgrades across technology, software, financial services, consumer discretionary,…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T04:20:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-06T04:32:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/11\/American-Analyst-Updates_-Wall-Street-Ratings-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"54 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"American Analyst Updates: Nov 5th, 2026\",\"datePublished\":\"2026-11-06T04:20:16+00:00\",\"dateModified\":\"2026-11-06T04:32:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/\"},\"wordCount\":11062,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News & Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/\",\"name\":\"American Analyst Updates: Nov 5th, 2026 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-11-06T04:20:16+00:00\",\"dateModified\":\"2026-11-06T04:32:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"American Analyst Updates: Nov 5th, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"American Analyst Updates: Nov 5th, 2026 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/","og_locale":"en_US","og_type":"article","og_title":"American Analyst Updates: Nov 5th, 2026","og_description":"Analyst Ratings (USA) Wall Street analyst outlook fot today remains mixed and increasingly cautious, with significant downgrades across technology, software, financial services, consumer discretionary,…","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2026-11-06T04:20:16+00:00","article_modified_time":"2026-11-06T04:32:14+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2026\/11\/American-Analyst-Updates_-Wall-Street-Ratings-1.png","type":"image\/png"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"54 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"American Analyst Updates: Nov 5th, 2026","datePublished":"2026-11-06T04:20:16+00:00","dateModified":"2026-11-06T04:32:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/"},"wordCount":11062,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News & Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/","name":"American Analyst Updates: Nov 5th, 2026 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-11-06T04:20:16+00:00","dateModified":"2026-11-06T04:32:14+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-updates-nov-5th-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"American Analyst Updates: Nov 5th, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=76855"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76855\/revisions"}],"predecessor-version":[{"id":76860,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76855\/revisions\/76860"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/76865"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=76855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=76855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=76855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}